American Capital Management Inc. Buys 205 Shares of Hologic, Inc. (HOLX)

American Capital Management Inc. boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,158,584 shares of the medical equipment provider’s stock after buying an additional 205 shares during the period. Hologic accounts for about 3.4% of American Capital Management Inc.’s investment portfolio, making the stock its 6th largest position. American Capital Management Inc. owned 0.41% of Hologic worth $52,577,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Victory Capital Management Inc. increased its stake in Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock worth $172,363,000 after buying an additional 3,269,503 shares during the last quarter. American Century Companies Inc. increased its stake in Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock worth $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Bank of Montreal Can increased its stake in Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock worth $136,448,000 after buying an additional 1,295,885 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in Hologic by 123.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,446,445 shares of the medical equipment provider’s stock worth $58,032,000 after buying an additional 798,541 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Hologic by 229.7% in the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock worth $48,100,000 after buying an additional 738,215 shares during the last quarter. Institutional investors and hedge funds own 94.43% of the company’s stock.

Hologic, Inc. (HOLX) opened at 37.42 on Friday. The stock has a market cap of $10.50 billion, a P/E ratio of 13.94 and a beta of 0.90. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80. The company’s 50-day moving average price is $42.62 and its 200-day moving average price is $42.82.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. During the same quarter last year, the firm earned $0.51 EPS. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. Analysts forecast that Hologic, Inc. will post $2.01 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “American Capital Management Inc. Buys 205 Shares of Hologic, Inc. (HOLX)” was first posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/american-capital-management-inc-raises-position-in-hologic-inc-holx-updated-updated.html.

HOLX has been the topic of a number of research reports. Goldman Sachs Group, Inc. (The) downgraded Hologic from a “conviction-buy” rating to a “buy” rating and lowered their price target for the company from $48.00 to $47.00 in a research report on Thursday, August 3rd. Stifel Nicolaus restated a “buy” rating on shares of Hologic in a research report on Friday, July 14th. BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Canaccord Genuity restated a “buy” rating and set a $53.00 price target on shares of Hologic in a research report on Tuesday, May 9th. Finally, Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $48.64.

In related news, Director Lawrence M. Levy sold 9,193 shares of the stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $42.93, for a total value of $394,655.49. Following the completion of the transaction, the director now owns 46,206 shares of the company’s stock, valued at approximately $1,983,623.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Elaine Ullian sold 6,902 shares of the stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the sale, the director now directly owns 23,810 shares in the company, valued at $955,257.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,551 shares of company stock valued at $2,244,458. 0.79% of the stock is owned by insiders.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply